Borrelia miyamotoi EliSpot

Description

A special type of disease associated with borreliae is infection caused by Borrelia miyamotoi. which was discovered in Japan in 1995. However, it can now be found all over the world.

In recent years, it has become increasingly common Borrelia miyamotoi is found in ticks
(England, Germany, USA, Russia, etc.), there have also been reported cases of .

Borrelia miyamotoi belongs to the group of relapsing fever pathogens and can cause symptoms such as: recurrent fever, chills, headache, joint and muscle pain, fatigue, nausea/vomiting, sometimes conjunctivitis and cough with an incubation period of 5-15 days.
Symptoms usually occur within 2-9 days. They may recur in periods of varying length or persist. Unlike infection with Borrelia burgdorferi, erythema migrans usually does not appear.

Atypical symptoms of an infection caused by Borrelia miyamotoithere could be: Abdominal pain, diarrhea, hepatitis, myocarditis, arrhythmias, pulmonary symptoms (e.g., ARDS), disseminated intravascular coagulation (DIC), facial nerve palsy, hearing loss, iritis (inflammation of the iris), polyneuropathy, or
neuropsychiatric disorders.

Laboratory diagnosis by antibody detection is not currently available in conventional laboratories.
ArminLabs performs assays to determine cellular activity against Borrelia miyamotoi using a certified ELISPOT method

ELISPOT (Enzyme-Linked ImmunoSpot) belongs to the group of laboratory tests IGRA (Interferon Gamma Release Assay - a test based on the determination of interferon gamma release by T-lymphocytes in contact with specific antigens).

At ArminLabs, the analysis ELISPOT is still used to diagnose infections caused by the following pathogens: Borrelia burgdorferi, Ehrlichia/Anaplasma, Chlamydia pneumoniae, Chlamydia trachomatis, Yersinia, Epstein-Barr virus, Cytomegalovirus, Herpes virus types 1,2.

German laboratory ArminLabs has now expanded its Elispot analytics and can now offer the analysis of Borrelia miyamotoi ELISPOT.

EliSpot assays are recommended 6 weeks after treatment completion to evaluate the effectiveness of the treatment.